VP-20621 is under clinical development by Destiny Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect VP-20621’s likelihood of approval (LoA) and phase transition for Clostridioides difficile Infections (Clostridium difficile Associated Disease) took place on 02 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VP-20621 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
VP-20621 is under development for the prevention of Clostridium difficile associated diarrhea (CDAD). The drug candidate is administered through oral route. VP-20621 is a formulation of spores of a non-toxigenic single strain of Clostridium difficile. The drug candidate is based on non-toxigenic spore-based technology.
Destiny Pharma overview
Destiny Pharma, formerly Destiny Pharma, is a drug development and discovery company. It offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to address multi drug resistant microbial pathogens that cause infections. Its pipeline products includes NTCD-M3, XF-73 and SPOR-COV. Destiny Pharma‘s products find applications for the treatment of clostridioides difficile infections, post surgical infections, dermal infections and COVID-19. The company has its operations through a network of industries, governments and academia. Destiny is headquartered in Brighton, East Sussex, the UK.
Quick View VP-20621 LOA Data
|Highest Development Stage|